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INTRODUCTION
The aging process is characterized by alterations of vari-
ous organs and systems that affect the total homeostatic 
capacity of the human body. As described for the first time 
by Irwin Rosenberg in 1989 in Albuquerque (New Mexico, 
USA), “from a structural and functional point of view, no 
decline is more dramatic than the one that muscle mass 
undergoes during the various decades of life”, and pro-
posed the term “sarcopenia” to define the loss of muscle 
mass and function that occurs in aging 1. The muscle mass 
and functional decline described by Rosenberg 30 years 
ago has been clearly documented with large observation-
al studies. Recent findings show that different patterns of 
muscle mass and physical decline with age are observed 
for different ages 2. In general, muscle mass slightly de-
creased with advancing age. Interestingly, for muscle 
strength (as measured by hand grip test) and physical 
performance (as measured by chair stand test) there is 
stability in the first decades of adulthood, and decrements 
in the middle years (45+) and late adulthood. In particular, 
individuals older than 75 years lose approximately 60% of 
their muscle strength and 30% of their physical function. 
The linear pattern of age-decline is surprisingly similar in 
men and women across the entire course of life, and is 
independent by different race 2.
Biological suBstrates of sarcopenia
Multiple factors are involved in the pathogenesis of 
sarcopenia 1 (Fig. 1): (a) constitutional factors, such as 
male sex, low birth weight, genetic susceptibility; (b) 
modifications related to the aging process itself. The 
latter factors can be schematized as follows:
• muscle cell alterations: including decreased type II cells 
– involved in rapid muscle power contraction and with 
a predominantly glycolytic metabolism -a size reduc-
tion of residual muscle cells, loss and disorganization 
of myofilaments, accumulation of lipofuscin pigments;
• age-dependent decline level of hormones: andro-
gens (testosterone and DHEA), estrogen, growth 
hormone (GH), and decline of insulin sensitivity; 
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• degeneration of spinal moto-neurons, probably due 
to a “retrograde effect”: the muscle, through largely 
unknown mechanisms, sends negative “remod-
eling” information to the motor terminal; 
• Mitochondrial dysfunction: in the muscles of sar-
copenic subjects, a significant deletion of the mito-
chondrial genome has been found caused by errors 
in DNA replication. The shorter genome replicates 
faster and induces the formation of malfunctioning or 
completely inactive mitochondria 3. This causes a cell 
energy deficit and the loss of the fiber itself, which is 
replaced by infiltration of connective and fatty tissue;
• increased protein turnover: since an adequate avail-
ability of nutrients, there is an imbalance between 
the ability of the fibers to complete a correct protein 
synthesis and the rate of degradation 4; 
• poor exercise and/or sedentary lifestyle: in this con-
nection, current evidence clearly shows that physi-
cal exercise may exert a positive impact on muscular 
physiology through systemic and local effects 7. 
Finally, a long list of chronic diseases (such as cognitive 
decline, mood disorders, diabetes mellitus, heart failure, 
liver failure, renal failure, respiratory failure, chronic pain, 
obesity) is related to sarcopenia, being the systemic 
inflammation a common pathologic pathway.
functional aspects
Among the diagnostic criteria of sarcopenia currently 
available, two are the most used: those developed in 
2010 during the European consensus on sarcopenia 
(EWGSOP)  8, and the more recent ones published in 
2014 by the group “FNIH Sarcopenia Project” 9. Both 
consensuses underline the importance of functional 
criteria in addition to the structural ones. The first cri-
teria are based on the detection of decreased muscle 
mass associated with strength or physical performance 
decline. The reference values for the diagnosis of sarco-
penia developed by the EWGSOP are 10:
• muscle mass: SMI (skeletal mass index) < 8.87 kg/
m2 for male; < 6.42 kg/m2 for female;
• pretension force < 30 kg for male; < 20 kg for fe-
male;
• physical performance <  0.8 m/s at the 4-meter 
walking test.
In 2014, as part of the “FNIH Sarcopenia Project”  9, 
analyzing data produced by 9 studies conducted on 
populations belonging to the community (for a total 
of 26,625 participants), a further conceptual step was 
carried out, with the aim of identifying clinically relevant 
thresholds of muscle mass and function. As a concep-
tual assumption, there was a clinical paradigm accord-
ing to which, starting from a patient with poor physical 
performance, you can identify in the differential diag-
nosis “weakness” as the causative agent of this and, 
subsequently, a reduction of the muscle mass at the 
base of the weakness itself. 
The identification of subjects in whom reduced mus-
cle mass is the main cause of weakness is crucial be-
cause they are able to gain significant benefit from the 
addressed interventions. The reference values for the 
diagnosis of sarcopenia developed by FNIH are 9:
• weakness: grip strength < 26 kg for male and < 16 
kg for female; alternative grip strength adjusted for 
BMI < 1.0 for male and < 0.56 for female.
• pppendicular lean body mass (ALM): ALM adjusted 
for BMI < 0.789 for male and < 0.512 for female; 
alternative ALM < 19.75 kg for male and < 15.02 kg 
for female.
The threshold values of the lean mass identified by the 
“FNIH Sarcopenia Project” as “clinically relevant” are as-
sociated with impairment of mobility. In a subsequent re-
search, Studensky also demonstrated that these cut-offs 
were not only clinically relevant, but also highly predictive 
of incident disability and mortality  11. Thus sarcopenia, 
and not multimorbidity, is strongly associated with ad-
verse outcomes. This fundamental evidence revolution-
izes the conceptual terms of the syndrome framework, 
especially considering that it represents a potentially 
reversible condition. Hence, it is important to refer to a 
clear and universal accepted operational definition, in 
order to develop adequate therapeutic interventions to 
prevent disability. Interventions will not target a pathol-
ogy, but functionality, revolutionizing the paradigm so far 
adopted towards patients in clinical practice. 
The updated EWGSOP2 recommendations indicate 
low muscle strength as the primary parameter of sarco-
penia, since this is the most reliable measure of muscle 
function, similarly to FNIH criteria. The diagnosis has 
to be confirmed by the detection of low muscle mass. 
The key conceptual step is represented by the fact that 
sarcopenia may be the biological substrate of physical 
frailty and the pathway through which it develops  12. 
Figure 1. Biological substrates of sarcopenia.
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Sarcopenia may be envisioned as the “organ failure” un-
derlying the clinical manifestations of physical frailty 13. 
Therefore, the implementation of this theoretic model 
will feasibly encourage important advancements over 
the traditional approaches to this syndrome by enabling 
the accurate operationalization of the disorder, a clear 
identification of the affected population, and the rapid 
translation of findings to the clinical setting. It is impor-
tant that such a conceptualization renders sarcopenia 
comparable to other common geriatric conditions, with 
the great benefit of making the syndrome easily accept-
able by health care professionals, public health authori-
ties, and regulatory bodies 14.
According to this conceptual model, sarcopenia re-
lies on a biological substrate at the muscle level (low 
muscle mass and quality). The clinical manifestations of 
sarcopenia, such as slow gait speed, impaired balance, 
and weakness, are also objectively measurable with 
specific assessment scales 15. This set of measurable 
biological substrate, clinical manifestations, and func-
tional performance is similar to the diagnostic path that 
is usually performed for other common age-related de-
generative conditions, such as congestive heart failure, 
chronic obstructive pulmonary disease, and peripheral 
artery disease  15. This implies that older persons with 
sarcopenia can be easily identified as those with target 
organ damage (muscle mass), specific clinical pheno-
type, and impaired physical performance 16.
 We present currently available tools for measuring 
muscle mass and physical function in order to better 
understand their advantages and limits, and their ap-
propriate use in clinical setting.
SCREENING OF SARCOPENIA IN CLINICAL 
PRACTICE
In every older patient presenting with weight loss, 
weakness, fatigue, frequent falls, and difficulties in ac-
tivities of daily living, the presence of sarcopenia should 
be evaluated. In this regard, the SARC-F questionnaire 
is a simple validated questionnaire should be admin-
istered during general medical examination to quickly 
identify subjects at risk of sarcopenia  17. It includes 5 
questions about difficulties to lift and carry 5 kg, walk-
ing across a room, transferring from a chair or bed, 
climbing 10 stairs, and numbers of falls in the previous 
year. Despite an uncertain sensitivity, a score ≥ 4/10 is 
reported to be predictive of sarcopenia and its nega-
tive outcomes 18. This screening test is considered as 
the first step in the identifications of sarcopenia by the 
revised version of 2EWGSOP 8.
Other recent studies tested different ways to predict 
sarcopenia in primary setting, such as probability tables 
based on low muscle mass by age and BMI, or predic-
tive score charts including variables such as age, hand-
grip strength, and calf circumference, but these need to 
be validated 17.
ASSESSMENT OF SARCOPENIA
It follows the list of methods for measuring muscle 
mass, useful in clinical practice or in research settings.
assessment of muscle mass
Anthropometric measures – calf circumference, mid-
arm muscle circumference 
Mid-arm muscle circumference (MAMC = mid-arm cir-
cumference – (3.14 X triceps skinfold thickness) and calf 
circumference have been show to reflect both health 
and nutritional status, and to predict performance and 
survival in older people, and have been shown to be cor-
related with ALM 19. The WHO Expert Committee con-
siders a calf circumference smaller than 31 cm indicative 
of low muscle mass  20. Anthropometry represents the 
most portable, easy to use, inexpensive tool, therefore it 
seems to be suitable for screening in primary care.
DXA – Dual energy X-ray absorptiometry
DXA is the most popular technique to estimate body 
composition, in particular appendicular skeletal lean 
mass  21. Based on the attenuation capacity of X-rays 
in proportion to the composition and thickness of a 
composite material, DXA is able to measure the body 
content of soft tissue, fat mass and total body (appen-
dicular and trunk) skeletal mass. Allowing measurement 
of the three body compartments and the estimation of 
appendicular skeletal lean mass (ALM) as the sum of 
the non-bone and non-fat mass of the four limbs (which 
is used both in EWGSOP and FNIH Sarcopenia pro-
ject diagnostic criteria), DXA is considered the current 
reference technique both in research and clinical prac-
tice for the assessment of muscle mass  21. The ALM 
is demonstrated to be strongly correlated with both 
MRI and CT measures of skeletal muscle volume. The 
main advantages of this tool are non-invasiveness (for 
the small doses of radiation: < 1 mSv for whole body 
scans)  22, cheapness, rapidity, and low rate of errors 
(1,2%). Weaknesses include that DXA is not portable, 
it is unable to assess intramuscular adipose tissue and 
consequently muscle quality; furthermore, its results 
could be affected by diseases associated with water 
retention (e.g. heart, kidney or liver failure), or with 
extracellular fluid accumulation, due to its inability to 
differentiate between water and bone-free lean tissue. 
Finally, the DXA machine usually does not support very 
tall or very obese people 21.
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Magnetic resonance imaging (MRI)
MRI gives high accuracy information about muscle 
quantity and quality: different tissues have different 
magnetic properties (such as density of hydrogen 
atoms and relaxation time), so variations in the radio 
frequency pulse sequence allow to differentiate adipose 
tissue and fat-free mass. Its use in clinical practice is 
limited by difficult access, high costs, long execution 
time, the need of high trained staff; it is suitable for 
small-scale research studies 23.
Computed tomography (CT)
CT produces images as maps of pixels which reflect 
different tissue attenuation (related to electron density): 
bone, skeletal muscle and adipose tissue have specific 
range, and this allow their identification in the cross-
sectional images. Strengths and weaknesses are very 
similar to MRI, except for radiation exposure and a 
shorter time for image acquisition 23.
Bioeletric impedance analysis (BIA)
BIA allows to quantify body compartments based on their 
different electrical conductivity: water rich tissue, such as 
skeletal muscle, are less resistant to the passage of an 
electrical current than lipid-rich adipose tissue 21. Whole-
body bioelectrical impedance measurement, in particular 
the resistance caused by the total water across the body, 
is taken between the right wrist and ankle with the sub-
ject in a supine position. The muscle mass is calculated 
through the Janssen equation (Skeletal muscle mass (kg) 
= [(height 2/BIA resistance X0.401) + (gender X 3.825) + 
(age X-0.071)] + 5.102).
Although BIA is a portable, easy to use, non-invasive, 
unexpensive tool, there is a poor correlation between 
BIA and DXA measurements (36), probability due to 
the fact that BIA measurements are very sensitive to 
subjects’ conditions such as hydration, recent activity 
and time being supine, body temperature, intra and 
inter-instrumental variability, and electrode positioning. 
Thus, BIA is suitable for screening of sarcopenia in 
community dwellers and bedridden patients 23.
Muscle ultrasonography (US)
The US beam propagates through and is reflected back 
to the transducer by tissues, according to their acous-
tic impedance; therefore, US allows the determination 
of thickness and cross-sectional areas of superficial 
muscle, and estimates muscle architecture parameters 
such as muscle volume, fascicle length, and pennation 
angle (which represents the angle of the muscle fibres 
relative to the force-generating axis, directly affect-
ing both the force production and the muscle excur-
sion)  24. Although the major issue that must be taken 
into consideration is the impact on the measurements 
result of the applied pressure on the probe, an excellent 
intra and inter rater reliability for US measurements of 
quadriceps muscle layer thickness has recently been 
reported. In addition, US is portable and radiation-free, 
being promising for muscle mass assessment in clinical 
and research settings 24.
Other approaches to estimate muscle mass
Neutron activation (NAA). A stationery neutron beam 
passes over the subject lying on bed. A gamma de-
tection system capturs gamma rays emitted by ex-
cited atomic nuclei, in turn excited by interaction with 
neutrons. Although very accurate in estimating muscle 
mass, this technique is not recommended for its high 
costs and radiation exposure 21.
Electrical impedance miography (EIM). It is based on 
the interpretation of muscle as a set of resistances and 
capacitances 21. Resistances, determined by intra and 
extracellular matrices, increase when muscle cross 
sectional area reduces; capacitances, constituted by 
cell lipid bilayer membranes, also increase in case of 
muscle loss. These quantitative parameters are meas-
ured by applying, through separated electrodes, a 
high-frequency/low-intensity electrical current. EIM is a 
non-invasive, painless tool to measure muscle mass, 
but it requires high trained personnel. Hence, is not ap-
plicable in daily clinical practice 21.
Serum and urinary creatinine. Creatine is a widely 
present amino acid in skeletal muscle  21. Creatine is 
non-enzymatically converted in creatinine at a relatively 
constant rate per day (about 2%) and excreted in urine. 
So, serum creatinine or 24-h creatinine excretion could 
be assumed to be proportional to the absolute amount 
of muscle mass 21. Measurement could be affected by 
many factors such as renal failure. Some Authors sug-
gested that, in the presence of stable renal function, 
it could be considered a reliable indicator of muscle 
mass, meat intake (accurate assessment would require 
a meat-free diet for about 1-2 weeks), inaccurate 24-h 
urine collection, conversion rate influenced by pH and 
temperature. Although predictive equations of creati-
nine excretion taking into account sex, weight, race 
and age have been developed, the absence of a normal 
range of reference does not make this technique cur-
rently applicable.
Deuterated creatinine (D3-creatine) dilution method. 
According to the non-enzymatic transformation just de-
scribed above, urine excretion of D3 creatinine can be 
quantified after an ingestion of oral dose of deuterated 
creatine, considering it an indirect measure of skeletal 
muscle mass 21. Although it is a complex technique that 
can only be used for research purposes, the estima-
tion of muscle mass with this method showed excellent 
concordance with MRI measurements of muscle mass 
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in rats and humans. Some researchers have tested the 
possibility of using muscle turnover circulating products 
(such as those of collagen types II and IV), as muscle 
mass biomarkers, but further studies are needed.
assessment of muscle strength
Hand grip strength 
The measurement of muscle strength by handgrip 
strength is currently recommended in clinical practice. 
For this aim, the gold standard is the use of a Jamar 
dynamometer, an isometric instrument composed of 
a hydraulic gauge, an adjustable handle and a display 
that indicates (in kg) the peak of strength reached dur-
ing the test  25. The standard exam is performed with 
the subject seated, and the grip size is adjusted for the 
first test hand. The examiner has to explain the test: the 
patient has to squeeze the hand grip as hard as he can 
with the forearm at the thigh level, taking a breath in 
before starting, and blowing out the air during the per-
formance. Six measures should be taken (3 per each 
arm) and the highest reading must be reported as the 
final result. This test presents some limitations in rela-
tion to the presence of arthritis, tendonitis, carpal tunnel 
syndrome, and surgery on hand or wrists in the previ-
ous three months. In these cases, physicians can use 
a pneumatic dynamometer to assess muscle strength.
In the case that sarcopenia could be viewed as a clinical 
biomarker to identify persons with a high risk of disabil-
ity and negative-related outcomes, hand grip strength, 
absolute or adjusted for BMI, assumes fundamental 
importance because it “can be considered a composite 
measure of muscle mass and muscle function and, at 
the same time, as an important discriminator of mobil-
ity limitation”  8. Considering this and the fact that it is 
portable, inexpensive and easy to perform, there is an 
urgent need to standardize reference values stratified 
for age, gender and ethnicity.
Leg extension strength
It is another test that measures lower body muscle iso-
metric strength. The participant sits with its lower legs 
hanging down (knee angle 90°). A resistance is fastened 
around the right lower leg of the participant, who must 
try to extend this leg with maximum strength and hold 
that position for 3 seconds. The score is given in kilo-
grams of force. After one practice trial, the best score of 
three trials is recorded. The main disadvantage consists 
in the need of an adequate equipment and trained staff.
assessment of physical performance 
Short Physical Performance battery (SPPB) 
Physical performance should primarily be assessed by 
Short Physical Performance Battery (SPPB) test. It es-
timates the lower body function and is highly correlated 
with disability and negative outcomes such as hospi-
talization, institutionalization and mortality, because it 
“provides an accurate picture of the biological age of 
an older person. At the same time, the SPPB is strongly 
related with the quantity and quality of skeletal muscle, 
and is therefore able to capture the core of Physical 
Frailty and Sarcopenia” 13.
The SPPB test includes balance tests, gait speed test, 
and chair stand test. In the balance tests, the partici-
pant first tries to stand for about 10 seconds with his 
feet together side by side, then with the side of the heel 
of one foot touching the big toe of the other foot for 
about 10 seconds, and finally with the heel of one foot 
in front of and touching the toes of the other foot for 
about 10 seconds. During the three tests, the patient 
could extend arms or move the body to maintain the 
balance, but not move the feet. The second test meas-
ures the 4 meters gait speed. The patient could use 
a cane and has two tries. The final test is the “chair 
stand test”: the subject stands up straight as quickly as 
he can five times without stopping in between, keep-
ing arms folded across the chest. The performance is 
considered good if chair stand time is ≤ 11.19 seconds. 
A total score < 9 is indicative of poor physical performance.
Time up and go test (TUG) 
The patient is seated in a chair. When the examiner 
says “go” the patient must get up, walk three meters 
(appropriately marked on the floor) at its usual gait, go 
back and sit again. The patient can use a walking aid 
if necessary. Time is recorded. Time ≥ 12 seconds to 
complete the TUG is considered an indication of poor 
physical performance.
Six minutes meters walking test
The patient must walk for 6 minutes along a corridor 
with a flat surface. The corridor must be at least 30 me-
ters long. Before and after the test, heart rate and blood 
pressure should be monitored. The six-minute walk 
distance in healthy adults has been reported to range 
from 400 m to 700 m. Age and sex-specific reference 
standards are available to identify individuals with poor 
physical function.
400 meters walking test 
The test is performed by asking the patient to walk for 
400  meters along a corridor having a flat surface  13. 
The patient could use a walking aid if necessary; the 
patient could stop at most 10  times. Each stop can 
last a maximum of 60 seconds, otherwise the test is 
interrupted. At the beginning and at the end of the test 
it is necessary to record the heart rate and the arterial 
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pressure. At the end of the test, the examiner must also 
investigate the perception of fatigue and the severity 
of the breathlessness with the Borg scale. A time ≥ 15 
minute to complete the 400-m walking test is consid-
ered an indicator of poor physical performance.
CONCLUSIONS
In clinical practice, EWGSOP2 new guidelines recom-
mend the use of the SARC-F questionnaire for screen-
ing. If it is positive, muscle strength should be measured 
by grip strength and chair stand test. The evidence of 
low muscle strength (probable sarcopenia) is enough to 
search the causes and start intervention. Low muscle 
quality or quantity should be detected to confirm the 
presence of sarcopenia; in this regard EWGSOP2 ad-
vise the use of DXA and BIA methods in usual clinical 
care, and DXA, MRI or CT in research. The measures 
of physical performance (SPPB, TUG and 400-m walk 
tests) should be used to assess severity of sarcopenia.
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